Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-3.89% $17.04
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 733.84 mill |
EPS: | -3.69 |
P/E: | -4.62 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 43.07 mill |
Avg Daily Volume: | 0.425 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.62 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.79x |
Company: PE -4.62 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.28 (-86.60%) $-14.76 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 15.99 - 18.05 ( +/- 6.04%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Savill Corrine | Buy | 37 500 | Common Stock |
2024-02-22 | Savill Corrine | Buy | 75 000 | Stock Option (Right to Buy) |
2024-02-22 | Ahmed Nadim | Buy | 320 000 | Stock Option (Right to Buy) |
2024-02-22 | Ahmed Nadim | Buy | 160 000 | Common Stock |
2024-02-22 | Trigilio Jeffrey | Buy | 50 000 | Common Stock |
INSIDER POWER |
---|
-16.82 |
Last 99 transactions |
Buy: 3 151 716 | Sell: 6 781 307 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $17.04 (-3.89% ) |
Volume | 0.372 mill |
Avg. Vol. | 0.425 mill |
% of Avg. Vol | 87.52 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $17.88 | N/A | Active |
---|
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.